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Heterodimer Partner by Protein Kinase C Is Critical for
Epigenomic Regulation of Liver Metabolic Genes*
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Background: Small heterodimer partner (SHP) is a key mediator of bile acid signaling.
Results:Bile acid signal-induced phosphorylation at Thr-55 by protein kinase C is important for SHP-mediated recruitment of
chromatin modifiers and histone modifications.
Conclusion: Thr-55 phosphorylation is critical for epigenomic regulation of liver metabolic genes.
Significance: SHP Thr-55 phosphorylation may potentially provide a therapeutic target for bile acid-related diseases.
Bile acids (BAs) are recently recognized key signaling mole-
cules that control integrative metabolism and energy expendi-
ture. BAs activate multiple signaling pathways, including those
of nuclear receptors, primarily farnesoid X receptor (FXR),
membrane BA receptors, and FXR-induced FGF19 to regulate
the fed-state metabolism. Small heterodimer partner (SHP) has
been implicated as a key mediator of these BA signaling path-
ways by recruitment of chromatin modifying proteins, but the
key question of how SHP transduces BA signaling into repres-
sive histone modifications at liver metabolic genes remains
unknown. Here we show that protein kinase C (PKC) is acti-
vated by BA or FGF19 and phosphorylates SHP at Thr-55 and
that Thr-55 phosphorylation is critical for the epigenomic coor-
dinator functions of SHP. PKC is coimmunopreciptitated with
SHP and both are recruited to SHP target genes after bile acid or
FGF19 treatment. Activated phosphorylated PKC and phos-
phorylated SHP are predominantly located in the nucleus after
FGF19 treatment. Phosphorylation at Thr-55 is required for
subsequent methylation at Arg-57, a naturally occurring muta-
tion site in metabolic syndrome patients. Thr-55 phosphoryla-
tion increases interaction of SHPwith chromatinmodifiers and
their occupancy at selective BA-responsive genes. This molecu-
lar cascade leads to repressive modifications of histones at met-
abolic target genes, and consequently, decreased BA pools and
hepatic triglyceride levels. Remarkably, mutation of Thr-55
attenuates these SHP-mediated epigenomic and metabolic
effects. This study identifies PKC as a novel key upstream reg-
ulator of BA-regulated SHP function, revealing the role of
Thr-55 phosphorylation in epigenomic regulation of liver
metabolism.
The function of bile acids (BAs)2 to facilitate digestion of
lipid nutrients is well known, but only recently have BAs been
recognized as key signaling molecules that control integrative
metabolism and energy expenditure (1–4). BAs are endoge-
nous ligands for nuclear BA receptors, primarily FXR, and
membrane BA G-protein coupled receptors, including TGR5
(1–3). Furthermore, BA-activated farnesoid X receptor (FXR)
induces expression of intestinal fibroblast growth factor 19
(FGF19, FGF15 is the mouse ortholog) that is secreted and acts
at the liver (5). After a meal, in addition to activation of FXR,
binding of BAs or BA-induced FGF19 to their hepatic mem-
brane receptors triggers signaling cascades that mediate post-
prandial responses, such as inhibition of BA and glucose syn-
thesis and stimulation of glycogen synthesis (6). However, little
is known about howBA signaling is transmitted to control tran-
scriptional programs of fed-state metabolism.
Accumulating evidence indicates that small heterodimer
partner (SHP) is a key mediator of BA signaling (5, 7–10). SHP
is an orphan nuclear receptor lacking a DNA binding domain
and acts as a transcriptional corepressor by inhibiting numer-
ous transcription factors, such as HNF-4, LRH-1, ERR, p53,
and NF-B, in diverse biological pathways including metabo-
lism, proliferation, and inflammation (11–14). Of these func-
tions, the role of SHP in maintaining BA homeostasis by inhib-
iting hepatic BA synthetic Cyp7a1 and Cyp8b1 genes is well
established (9, 10, 15). Our group has shown that in response to
elevated hepatic BA levels, SHP represses the Cyp7a1 gene by
coordinately recruiting repressive chromatin modifying cofac-
tors, HDAC-containing mSin3A and NcoR corepressor com-
plexes, G9a methyltransferase, and the Brm-containing Swi/
Snf remodeling complex, resulting in sequential epigenomic
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modifications at the promoter (16–18). However, the key ques-
tion of how BAs trigger increased recruitment of SHP-associ-
ated chromatin modifiers and consequently epigenomic regu-
lation is not known.
Post-translational modifications (PTMs) of regulatory pro-
teins like SHP profoundly modulate their cellular function by
altering protein interactions, nuclear localization, and protein
stability. For more than a decade, the prevailingmechanism for
increased hepatic SHP activity was its transcriptional induction
by FXR (9, 10).We have recently shown that repression activity
and protein stability are also regulated by BA signal-induced
PTMs of SHP (8, 19). Relevant to this study, SHP is methylated
at Arg-57 by PRMT5 methyltransferase upon BA treatment
and this methylation enhances SHP activity by selectively
increasing its interaction with repressive chromatin modifiers
(19). Remarkably, a naturally occurring mutation of Arg-57 to
Trp in SHP is associated with metabolic syndrome (20). Here
we show that an atypical protein kinase C (PKC) is activated
by BA or FGF19 signaling and phosphorylates SHP at Thr-55
and that Thr-55 phosphorylation of SHP is important for the
epigenomic coordinator function of SHP in the regulation of
fed-state liver metabolism.
EXPERIMENTAL PROCEDURES
Reagents—Antibodies were purchased for SHP (sc-30169),
lamin A (sc-20680), tubulin (sc-8035), HDAC1 (sc-7872), Brm
(sc-6450), LRH-1 (sc-5995X), HNF-4 (sc-8987), PGC1 (sc-
13067), RNA pol II (sc-9001), GFP, (sc-8334), -tubulin (sc-
5274), and actin (sc-1616) from Santa Cruz Biotechnology; for
Foxa-2 (number 3143), phospho-Thr (number 9381), phospho-
PKC (number 9378), and PKC (number 9368) from Cell Sig-
naling; for H3K9/K14-Ac (number 06-599), H3K9-me2 (num-
ber 07-030), H3K4-me3 (number 07-521), and G9a from
Millipore; and M2 from Sigma. The siRNA for PKC was pur-
chased from Ambion and siRNA for ERK and control siRNA
were purchased from Applied Biosystems. A phospho-Thr-55-
specific SHP antibody was produced commercially (Abmart,
Inc.).
Animal Experiments—Male BALB/c male mice (8–12 weeks
old) were injected via the tail vein with Ad-FLAG-SHP WT or
T55A mutant (0.5–1.0  109 active viral particles in 200 l of
PBS), which resulted in SHP levels about 10-fold greater than
endogenous SHP (data not shown). This is comparable with
5–6-fold increases in SHP compared with endogenous levels in
SHP liver-specific transgenic mice and to hepatic SHP levels in
response to BA signaling (21). The construction of Ad-FLAG-
SHP WT has been described previously (19). The adenovirus
selectively infects the liver so that little or no expression occurs
in other tissues (22). Five to 7 days after infection, themicewere
fasted for 5–6 h and treated for 15 min with 1 mg/kg of FGF19
injected i.v. or fed 0.5%CA-chow (Harlan Teklad TD05271) for
3 h. BA pools were measured by colorimetric analysis (Trinity
Biotechnology). Liver triglyceride (TG) levels were measured
using a kit (TR0100, Sigma). For glucose tolerance test, mice
were fasted for 6 h and injected intraperitoneally with glucose
solution (Sigma, 2 g/kg of body weight), and blood glucose lev-
els weremeasured using a glucometer (RocheApplied Science).
All animal use and adenoviral protocols were approved by the
Animal Care and Use and Biosafety Committees at the Univer-
sity of Illinois at Urbana-Champaign.
Tandem Mass Spectrometry Analysis—FLAG-human SHP
was adenovirally expressed in HepG2 cells and 48 h later, the
cells were treated with 5 M MG132 for 4 h to inhibit protea-
somal degradation of SHP (8) and then treated with chenode-
oxycholic acid (CDCA) for 1 h. FLAG-SHP was isolated using
M2-agarose, proteins were separated and visualized by colloi-
dal staining; and bands containing FLAG-SHP were subjected
to MS/MS analysis.
IP/IB-based Phosphorylation Assay—Endogenous SHP or
FLAG-SHP was immunoprecipitated with 1 g of SHP anti-
body or M2 antibody, respectively, for 30 min in IP buffer (50
mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% Nonidet
P-40, 2mM EDTA, and 5% glycerol). Then, 35l of 25% protein
G-agarose was added, and 2 h later samples were washed with
IP buffer, and SHP phosphorylated at Thr was detected by IB
using phospho-Thr antibody or specific phospho-Thr-55
antibody.
In Vitro PKC Assay—HepG2 cells were infected with Ad-
FLAG-SHP WT or T55A, and 24 h later, cell extracts were
prepared in lysis buffer (1% Nonidet P-40, 50 mM Tris-HCl, pH
8.0, 150 mM NaCl). FLAG-SHP was isolated by affinity to
M2-agarose beads and the beads were washed with the lysis
buffer and then with kinase buffer (50 mM Tris-HCl, pH 7.5, 10
mMMgCl2, 1 mM DTT). FLAG-SHP bound to M2-agarose was
incubated with 20 M ATP and 20 ng of purified PKC (Milli-
pore) in kinase buffer at 30 °C for 30 min. To determine the
effect of FGF19 or CDCA treatment on PKC activity, HepG2
cells were infected with Ad-PKC (23) and treated with vehicle
or FGF19 or CDCA for 15min, PKCwas immunoprecipitated,
and kinase activity was determined in in vitro assays with puri-
fied FLAG-SHP as substrate.
Co-IP, GST Pull-down, and Reporter Assays—Cell extracts
were prepared in co-IP buffer (50 mM Tris, pH 8.0, 150 mM
NaCl, 2 mM EDTA, 0.3%Nonidet P-40, 10% glycerol) and incu-
bated with 1–2 g of antibodies for 30 min, and 35 l of 25%
protein G-agarose was added. Two h later, samples were
washed with the co-IP buffer and interacting proteins were
detected by IB. GST pull-down and reporter assays were per-
formed as described previously (19, 24, 25).
Immunofluorescence Cellular Localization Assays—HepG2
cells were incubated with serum-free media overnight and
treatedwith vehicle or FGF19 for 15min. After fixationwith 4%
paraformaldehyde for 25 min, cells were treated with 0.5% Tri-
ton X-100/PBS for 15 min, incubated with primary antibody
(dilution 1:200 in PBS) for 2 h and secondary antibody Texas
Red goat anti-rabbit IgG (dilution 1:200 in PBS) for 1 h. Nuclei
were labeled with DAPI (dilution 1:1000) for 5 min. Images
were taken and processed using ZEN software (Zeiss LSM700).
Chromatin Immunoprecipitation (ChIP) Assays—ChIP
assays were performed as previously described (17–19, 25, 26).
Briefly, livers were finelyminced and incubated in PBS contain-
ing 1% formaldehyde for 10 min, and glycine was added to stop
the reaction. Cells were resuspended in hypotonic buffer and
lysed by homogenization. Nuclei were pelleted and sonicated.
The chromatin sample was precleared and chromatin was
immunoprecipitated using 1–1.5 g of antibody. For re-ChIP
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assays, FLAG-SHP was immunoprecipitated first by M2 anti-
body, eluted by adding 50l of 10mMDTT at 37 °C for 30min.
Then, chromatin samples were diluted (20-fold) with buffer (20
mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton
X-100) and re-precipitated using antibodies as indicated. Chro-
matin was extensively washed, eluted, and the amounts of
genomic DNA were determined by PCR. Primer sequences for
semi-qPCR have been previously described (19) and qPCR
primer sequences are available upon request.
RT-qPCR—Total RNA was isolated and cDNA was synthe-
sized using a reverse transcriptase kit (Promega), and RT-
qPCR was performed. Primer sequences are available upon
request.
RESULTS
SHP Is Phosphorylated at Thr-55 in Response to BA or FGF19
Signaling—To identify BA signal-induced phosphorylation
site(s) in SHP, purified SHP was analyzed by tandem mass
spectrometry. SHP was phosphorylated at Thr-55 after
treatment of HepG2 cells with a primary BA, CDCA (Fig.
1A). Treatment with CDCA or FGF19 resulted in increased
Thr phosphorylation of FLAG-SHP (Fig. 1B), but these
effects were not observed with GW4064, a synthetic agonist
for FXR (Fig. 1C). Thr phosphorylation of endogenous SHP
was also increased in HepG2 cells after CDCA or FGF19
treatments (Fig. 1D) and inmouse liver after FGF19 injection
FIGURE 1. Phosphorylation of SHP at Thr-55 in response to BA or FGF19 signaling. A, tandem mass (MS/MS) spectrum of the SHP peptide showing
phosphorylation of Thr-55 (T∧, phosphorylated Thr-55; T#, Thr-55 with loss of water; R*, methylated Arg-57). FLAG-SHP expressed in HepG2 cells treated with
CDCAwas isolated, visualizedby colloidal staining, andexcised forMS/MSanalysis.B andC,phospho-Thr levels of FLAG-SHP inHepG2cells treatedwith FGF19,
CDCA, or GW4064 for 1 h were detected by IP of FLAG-SHP followed by IB using phospho-Thr antibody. D and E, phospho-Thr levels of endogenous SHP in
mouse liver or HepG2 cells treated with FGF19 or CDCA are shown. In B and E, bands were quantified and phosphor-Thr SHP levels relative to untreated cells
(CTL) shown (right panel) and statistical significance was determined by the Student’s t test, * indicates p  0.05, S.E., n  3. F, FLAG-SHP WT or T55A was
expressed in HepG2 cells and phospho-Thr SHP was detected by IP/IB analysis. G and H, the experimental outline is shown at the top. Phospho-Thr-55 of SHP
in liver extracts was detected by IP/IB analysis using general phosphor-Thr antibody (G) or phosphor-Thr-55-specific SHP antibody (H). FLAG-SHP and control
GFP from the adenoviral infection are shown at the bottom. I, phosphorylation of endogenous SHP at Thr-55 in mouse liver extracts was detected by IB using
a phosphor-Thr-55-specific SHP antibody. J, alignment of the SHP region containing Thr-55 (underlined) from various species.
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(Fig. 1E). A large fraction, roughly 70%, of total hepatic SHP
proteins was phosphorylated after FGF19 treatment (data
not shown). Importantly, mutation of Thr-55 (T55A) abol-
ished phosphorylation of SHP, identifying Thr-55 as the site
of BA-induced Thr phosphorylation (Fig. 1F).
To determine whether SHP is phosphorylated in vivo at Thr-
55, a phospho-Thr-55-specific SHP antibody was developed.
To assess the specificity of antibody, mice were injected with
adenoviral vectors expressing SHP wild type (WT) or a phos-
phorylation-defective T55A mutant and phosphorylation of
SHP was detected with a phospho-Thr antibody or with the
phospho-Thr-55-specific SHP antibody. Robust Thr phospho-
rylationwas detected in FGF19-treatedmice expressing FLAG-
SHP WT, but was not detectable in mice expressing the T55A
mutant (Fig. 1G). Importantly, phosphorylation inWT, but not
in the T55A mutant, was detected by the phosphor-Thr-55-
specific SHP antibody, demonstrating the specificity of this
antibody (Fig. 1H) and confirming that Thr-55 is the major site
of phosphorylation in exogenously expressed FLAG-SHP in
vivo. Using this site-specific antibody, we also confirmed that
endogenous SHP in mouse liver is phosphorylated at Thr-55
after FGF19 treatment (Fig. 1I) and that Thr-55 phosphoryla-
tion of FLAG-SHP was increased in response to FGF19 or
CDCA in HepG2 cells (data not shown). These results demon-
strate that SHP is phosphorylated at Thr-55 in response to BA
or FGF19. Notably, the Thr-55 is well conserved in vertebrates
(Fig. 1J), suggesting that phosphorylation at Thr-55 of SHPmay
be functionally important.
Thr-55 in SHP Is Phosphorylated by PKC upon BA/FGF19
Signaling—To identify the kinase(s) catalyzing the Thr-55
phosphorylation of SHP, we utilized both pharmacological
inhibitors and siRNA.We first used inhibitors of kinases poten-
tially involved in BA/FGF19 signaling pathways (4, 6, 27).
Treatment with inhibitors of PI3K or PKC decreased Thr
phosphorylation of SHP induced by FGF19 or CDCA (Fig. 2A).
In contrast, treatment with inhibitors of PKC (Fig. 2A), ERK,
JNK, PKB (Fig. 2B), or p38 kinase (data not shown) did not
reduce the phosphorylation levels. Because some of these
inhibitors are not specific and ERK has been shown to be acti-
vated by BA or FGF19 treatment (6, 27), we confirmed our
FIGURE 2. PKC phosphorylates SHP at Thr-55 upon BA/FGF19 signaling. A and B, HepG2 cells infected with Ad-FLAG-SHP were treated with each kinase
inhibitor as indicated, for PKC (G06983, 1 mM), PI3K (wortmannin, 100 nM), PKC (myristoylated PKC pseudo-substrate, 20 M; or PKC pseudo-substrate, 20
mM), p38 (SB203580, 5M), ERK (PD98059, 20M), or JNK (SP600125, 20M) for 30min and then further treated with FGF19 or CDCA for 15min. Phospho-Thr
levels of SHPweredetectedby IP/IB analysis. Consistent resultswereobserved in 2–4experiments.C,HepG2cellswere transfectedwith siRNAas indicated and
24 h later, cells were infectedwith Ad-FLAG-SHP, and then 24 h later treatedwith FGF19 for 15min. Phospho-Thr levels of SHPwere detected by IP/IB analysis.
In the right panel, phospho-Thr SHP relative to the untreated control siRNA in lane 1 are shown and statistical significance determined by the Student’s t test,
* and **, and NS indicate p 0.05, p 0.01, and statistically nonsignificant, respectively, S.E., n 3. D, HepG2 cells of mice were treated with FGF19 or CDCA
for 15min and phospho- or total PKC levels were detected. E, co-IP, the interaction of FLAG-SHPwith PKCwas detected by co-IP assays in HepG2 cells. F,GST
pull-down, schematic diagrams of domains of SHP are shown at the top. Amounts of input GST or GST-SHP proteins are shown (middle) and PKC proteins
bound to GST-SHP proteins were detected (bottom). G, experimental outline for the in vitro kinase assay is shown (left panel). Phospho-Thr-55 levels of
FLAG-SHP WT were detected by IP/IB or IB analysis (right panel). H, experimental outline for the in vitro kinase assay is shown (top) and phospho-Thr levels of
FLAG-SHP WT or T55A mutant were detected by IP/IB analysis (upper panel). Total PKC and SHP levels are shown below.
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findings using siRNA for PKC or ERK. Down-regulation of
PKC abolished Thr phosphorylation by FGF19, whereas phos-
phorylation of SHP was not inhibited by down-regulation of
ERK (Fig. 2C). Consistently, levels of the active phosphorylated
form of PKC were elevated in HepG2 cells or in mice after BA
or FGF19 treatment (Fig. 2D). These results suggest that the
PI3K/PKC pathway is activated upon BA signaling and that
PKC phosphorylates SHP at Thr-55.
To further support this conclusion, the interaction of SHP
with PKC was studied. In co-IP studies, FGF19 treatment
increased the interaction of SHPwithPKC and this interaction
was not observed for the phosphorylation-defective T55A
mutant (Fig. 2E). In vitro GST pulldown assays showed that
SHP directly interacted with PKC through the N-terminal
domain of SHP (Fig. 2F).
To determine whether PKC is activated by BA or FGF19
treatment, PKC was overexpressed in HepG2 cells and cells
were treated with vehicle, FGF19, or CDCA. PKC was immu-
noprecipitated and its activity was assessed in in vitro kinase
assays (Fig. 2G, left panel). In response to either FGF19 or
CDCA treatment, phosphorylation of both PKC and SHP,
detected by the phosphor-Thr-55-specific antibody, was sub-
stantially increased (Fig. 2G, right panel). Moreover, Thr phos-
phorylation of SHP was observed for FLAG-SHP WT, but not
the T55Amutant (Fig. 2H). These results demonstrate that BA
signaling results in activation of PKC and phosphorylation of
SHP at Thr-55.
Effects of FGF19 or BA on Nuclear Localization of PKC and
SHP—We next examined the effect of FGF19 or BA treatment
on the cellular localization of phosphorylated PKC and SHPby
immunofluorescence studies. PKC and phosphorylated PKC
were localized exclusively in the cytoplasm in untreated cells
and FGF19 treatment resulted in a dramatic increase in the
levels of both forms of PKC in the nucleus (Fig. 3, A and B).
SHP was localized in both the cytoplasm and nucleus and
FGF19 treatment resulted inmodest increases in nuclear abun-
dance (Fig. 3C). Strikingly, however, low levels of SHP phos-
phorylated at Thr-55 were detected in the cytoplasm in
untreated cells, but levels were dramatically increased and
nearly exclusively localized in the nucleus after FGF19 treat-
ment (Fig. 3D). These results confirm that PKC is activated by
FGF19 signaling and suggest that SHP is phosphorylated by
PKC in the nucleus. Consistent with these results, in biochem-
ical fractionation studies inmice in vivo, SHPWTwas localized
in both the cytoplasm and nucleus, but the T55A phosphoryla-
tion-defective SHP mutant was predominantly located in the
cytoplasm (data not shown). These results suggest that the
phosphorylation of SHP at Thr-55 is likely important for reten-
tion of SHP in the nucleus.
The nuclear localization of activated PKC suggested the
possibility that PKC might be co-recruited with SHP to its
target genes. To test this possibility, liverChIP assayswere done
in mice treated with FGF19 or CA. Recruitment of PKC was
compared with that of ERK and PRMT5, whichmodulate PTM
FIGURE3.Effectsof FGF19orBAsignalingonnuclear localizationofPKCandSHP.A–D, immunofluorescence cellular localization study.HepG2cellswere
treatedwith vehicle (Veh) or FGF19 for 15minand localizationof PKC andSHPwasdetectedbyantibodyagainst phosphor-PKC, PKC, phosphor-SHP, or SHP.
Nuclei were stainedwith DAPI. Merged images are shown below. E and F, ChIP:micewere treatedwith FGF19 (15min) or fed CA chow (3 h), livers were pooled
from 3mice, and ChIP assays were performed.
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of SHP in response to BA or FGF19 signaling (8, 19). In mice
treatedwith FGF19 or fedCAchow, occupancies of SHP, PKC,
PRMT5, and ERK (8, 19) were increased at the Cyp7a1 pro-
moter (Fig. 3, E and F). Conversely, occupancy of RNA polym-
erase II was decreased, consistent with the suppression of
Cyp7a1 expression by SHP. These results, collectively with cel-
lular localization studies and co-IP protein interaction studies
above, suggest that PKC is activated by BA or FGF19 signaling
and phosphorylates SHP at Thr-55, possibly by co-localizing
with SHP at its target genes.
Thr-55 Phosphorylation Is Essential for Arg-57 Methylation—
We showed recently that SHP is methylated at Arg-57 by
PRMT5 in response to BA signaling and that thismethylation is
important for SHP repression activity (19). We, therefore, fur-
ther examined possible functional cross-talk between Arg-57
methylation and Thr-55 phosphorylation. Mutation of Thr-55
(T55A) largely abolished methylation of Arg-57 after FGF19
treatment, whereas mutation of Arg-57 (R57W) did not affect
Thr-55 phosphorylation (Fig. 4A). Similar results were
observed when the cells were treated with CDCA (Fig. 4B).
Consistent with these results, the interaction of SHP with
PRMT5, which catalyzes methylation at Arg-57, was impaired
by mutation of Thr-55, as detected in co-IP studies (Fig. 4, C
and D). These results indicate that PKC-mediated Thr-55
phosphorylation is likely a key upstream event that is required
for Arg-57 methylation upon BA signaling.
Thr-55 Phosphorylation Is Important for SHP Repression
Activity—To determine the functional relevance of Thr-55
phosphorylation, cell-based reporter assays were performed.
Expression of SHP WT decreased HNF-4-mediated transacti-
vation in HepG2 cells treated with either FGF19 (Fig. 5A) or
CDCA (Fig. 5B). These SHP-mediated repression effects were
substantially impaired for the phosphorylation-defective T55A
mutant, but, in contrast, enhanced with the phosphorylation
mimic T55Dmutant. Similar results were observed with a pro-
moter-luciferase reporter forCyp7a1 (Fig. 5,C andD). Because
Thr-55 phosphorylation is required for Arg-57 methylation
(Fig. 4), the effects of the Thr mutation were compared with
Arg-57 mutation. Increasing amounts of SHP WT decreased
LRH-1 transactivation and this repression was reversed by the
R57K mutation similar to, but to a slightly less extent than, the
FIGURE 4. Thr-55 phosphorylation of SHP is required for Arg-57methyla-
tion. A and B, HepG2 cells were infected with Ad-FLAG-SHP WT, T55A, or
R57W, and treatedwith FGF19orCDCA for 15min, andphosphorylatedThr or
methylated Arg levels were detected by IP/IB analysis. In the right panels,
levels of phospho-Thr SHP or methyl-Arg SHP levels were quantified relative
toWT are shown and statistical significancewas determined by the Student’s
t test, *, indicates p  0.05, S.E., n  3. C and D, co-IP: HepG2 cells were
transfectedwith an expression plasmid for PRMT5 and FLAG-SHPWT or T55A
mutant and then treated with FGF19. Interaction of SHP with PRMT5 was
detected by co-IP. On the top ofD is a diagram illustrating the dependence of
Arg-57 methylation by PRMT5 on Thr-55 phosphorylation by PKC.
FIGURE 5. Thr-55 phosphorylation is important for SHP repression activ-
ity. A–F, HepG2 cells were transfectedwith plasmids as indicated and treated
with either FGF19 (8 h) or CDCA overnight and reporter assays were per-
formed. The triangle indicates increasingamounts of the SHPexpressionplas-
mids. The values for firefly luciferase activities were normalized by-galacto-
sidase activities. The mean S.E. are plotted (n 3). G, expression levels of
SHP WT and the mutants from cell extracts are shown.
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reversal by the T55A mutation (Fig. 5, E and F). Similar
amounts of SHP WT and mutant proteins were expressed in
cell-based reporter assays (Fig. 5G). These results suggest that
Thr-55 phosphorylation augments the SHP repression activity
and this may be, at least in part, mediated by methylation at
Arg-57 that is dependent on Thr-55 phosphorylation.
Thr-55 Phosphorylation Selectively Increases Occupancy of
SHP-interacting Chromatin Modifiers at BA-responsive Target
Genes—To elucidate the molecular basis underlying the
enhanced SHP repression activity by Thr-55 phosphorylation,
we first examined the effect of mutation of Thr-55 of SHP on
interaction with its known transcription regulators. FGF19
treatment dramatically increased the interaction with known
SHP-interacting transcriptional factors LRH-1 and HNF-4,
coactivator PGC-1, and chromatin modifiers G9a and Brm
(Fig. 6A). With the exception of G9a, SHP interaction with
these proteins was nearly abolished bymutation of Thr-55 (Fig.
6A). These results suggest that Thr-55 phosphorylation is crit-
ical for interaction of SHP with transcription factors and some
of its associated chromatin modifying proteins.
Because the interaction of SHP with LRH-1/HNF-4, which
should increase SHP recruitment at its target genes, was
decreased by mutation of Thr-55 (data not shown), we next
determined the effects of mutation of Thr-55 on promoter
occupancy of SHP (Fig. 6B). Occupancies of FLAG-SHP were
examined at BA-responsive SHP target genes,Cyp7a1, Cyp8b1,
and Shp genes, which contain LRH-1/HNF-4 sites at their pro-
moters (15, 18, 19). FLAG-SHP was immunoprecipitated with
M2 antibody first and then re-immunoprecipitated with SHP
antibody. Treatment with FGF19 or CA feeding increased SHP
occupancy at the Cyp7a1 and Cyp8b1 genes, which was
decreased with the T55A mutant (Fig. 6, C and D). In contrast,
mutation of Thr-55 did not substantially decrease SHP occu-
pancy at the Shp promoter. These results indicate that Thr-55
phosphorylation is important for recruitment of SHP in a gene-
specific manner.
We next determined the effects of mutation of Thr-55 on
recruitment of SHP-associated transcriptional regulators.
Although treatment with FGF19 or CA did not change HNF-4
occupancy, the occupancy of HDAC1/2, G9a, and Brm was
increased with FLAG-SHP WT, but recruitment of HDAC1/2
and Brmwas reduced inmice expressing the T55Amutant (Fig.
6, E and F). In contrast, the mutation did not affect recruitment
of G9a, which is consistent with the co-IP studies presented
above (Fig. 6A). SHP inhibits its own expression by recruiting
these repressive histone modifiers, including Brm, to its own
promoter (18). Indeed, FGF19 treatment or CA feeding
increased occupancy of G9a and Brm, at the Shp promoter and
FIGURE 6. Thr-55 phosphorylation increases SHP interaction with repressive chromatin modifiers and their recruitment to BA-responsive target
genes. A, co-IP: transcriptional regulators were immunoprecipitated and the presence of FLAG-SHP was detected by M2 antibody. B–F, sequential liver
chromatin IP. B, experimental outline. C–F, chromatin was immunoprecipitated with M2 antibody, eluted, and re-precipitated with antibody as indicated.
Precipitated genomic DNA was quantified by semi-qPCR.
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the Thr-55 mutation had little effect on these changes (Fig. 6, E
and F). These results collectively demonstrate that Thr-55
phosphorylation of SHP is important for recruitment of chro-
matin modifiers to a subset of BA target genes.
Thr-55 Phosphorylation of SHP Is Important for Epigenomic
Events at a Subset of BA-responsive Genes—We further investi-
gated in vivo the effects of mutation of Thr-55 on histonemod-
ifications at SHP target genes. BA-responsive SHP target genes
involved in BA, fatty acid, and glucose metabolism, Cyp7a1,
Cyp8b1, Srebp-1c, and Pepck,were examined (15, 18, 19). Upon
FGF19 treatment, levels of histone H3 acetylated at K9/14 and
tri-methylated at K4, two well known gene activation histone
marks (28), were decreased at all of these genes inmice express-
ing SHPWT, but not inmice expressing the T55Amutant (Fig.
7A). Interestingly, di-methylated histone H3K9 (K9-me2), a
known gene repression mark catalyzed by G9a (17, 28, 29), was
increased after FGF19 treatment in both SHP WT and T55A
(Fig. 7A). In contrast, at the Shp promoter, levels of gene acti-
vation histone marks, H3K9/14-Ac and H3K4-me3, were
increased and levels of a gene repression mark, H3K9-me2,
were decreased and the T55A mutant did not have marked
effects on histone modifications (Fig. 7A). Strikingly, the genes
overall epigenomic events for mice fed CA chow (Fig. 7B) were
similar to those observed after FGF19 treatment. The occu-
pancy of SHP and chromatin modifying factors and histone
modifications were confirmed at the Cyp7a1 promoter using
ChIP-qPCR analysis (Fig. 7C, D). Collectively, these findings
indicate that Thr-55 phosphorylation of SHP is important for
BA signal-induced epigenomic regulation of a subset of liver
metabolic genes.
Functional Consequences of Thr-55 Phosphorylation of SHP
in Vivo—Finally, we determined the functional consequences
of mutation of Thr-55 in SHP in vivo (Fig. 8A). Acute hepatic
overexpression of SHP WT or T55A resulted in repression of
the BA-responsive target genes involved in BA synthesis and
transport, lipogenesis, and gluconeogenesis, whereas expres-
sion increased for genes involved in FA transport and -oxida-
tion (Fig. 8B). Remarkably, the effects of mutation of Thr-55
were gene-dependent. For most genes, the T55A mutation at
least partially reversed the induction or repressionmediated by
SHP WT (Fig. 8B). For repressed BA synthetic and lipogenic
genes, expression with T55A was greater than with the Ad-
empty control, suggesting that T55A acts in a dominant nega-
tivemanner to inhibit endogenous SHP activity. In contrast, for
FIGURE 7. Thr-55 phosphorylation of SHP is critical for epigenomic events at livermetabolic genes.Micewere tail vein injectedwith Ad-FLAG-SHPWTor
T55A and 7 days later, mice were treated with FGF19 or fed CA chow, and liver ChIP assays were performed. Chromatin was immunoprecipitated with M2
antibody first and re-precipitated with antibody as indicated. Precipitated DNA was quantified by semi-qPCR (A and B) and qPCR (C and D).
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a subset of genes, Bsep, CytC, CD36, and Srb1, the SHP effects
were not significantly affected by mutation of Thr-55. Consis-
tent with these patterns of gene expression, acute overexpres-
sion of SHP WT decreased the BA pool sizes and hepatic TG
levels, whereas these effects were not observed for the Thr-55
mutant (Fig. 8C). Notably in contrast, the effects of the Thr-55
mutation on expression of gluconeogenic genes, Pepck andGlc-
6-pase, were absent or relatively modest compared with the
genes involved in BA and FA synthesis. In line with these
results, glucose tolerance was improved inmice overexpressing
SHP WT and was still markedly improved with the T55A
mutant (Fig. 8D). These findings, together with the in vitro and
in vivo studies, indicate that Thr-55 phosphorylation of SHP by
PKC is important for transmitting BA signals, resulting in
selective transcriptional and metabolic responses in liver.
DISCUSSION
This study demonstrates the critical role of phosphorylation
of SHP by PKC at a single site, Thr-55, in epigenomic regula-
tion of the fed-state hepaticmetabolism. As summarized in Fig.
9, binding of BA or FGF19 to their respectivemembrane recep-
tors triggers signaling cascades in hepatocytes, which results in
the activation of downstream signaling pathways including the
PI3K/PKC pathway. Although activated PKC is present in the
cytoplasm as well as the nucleus, it is not clear whether PKC is
activated before or after translocation into the nucleus in
response to BA signaling. BA also binds to FXR and induces
BA-responsive genes, including Shp. Activated PKC, localized
in the nucleus, phosphorylates SHP at Thr-55 and possibly
other regulatory proteins as well. Thr-55 phosphorylation
increases the SHP interaction with PRMT5, which is required
for subsequent Arg-57 methylation. These sequential PTMs
selectively increase the SHP interaction with repressive chro-
matin modifying cofactors, HDACs and Brm, and recruitment
of these proteins to a subset of BA-responsive genes, resulting
in histone modifications and gene repression (16–18). Phos-
phorylated PKC, as well as PRMT5, is also recruited to SHP
target genes andmay be in the same SHP complex that contains
chromatin modifiers at BA-responsive SHP target genes but
this has not been established. PKC and PRMT5 may catalyze
PTMs of histones in addition to regulator factors. Epigenomic
events mediated by signal-induced PTMs of SHP contribute to
postprandial responses including decreased BA and TG levels.
This study reveals several intriguing features of BA signaling
pathways and the PTMs that modulate SHP activity. First, BA
and FGF19 signaling both resulted in Thr-55 phosphorylation
by PKC, although different hepatic membrane receptors initi-
ate their signaling cascades, which suggests that these two path-
ways converge before PKC phosphorylation of Thr-55. In
addition, epigenomic events triggered by BA or FGF19 signal-
ing at the selected SHP target genes tested were strikingly sim-
FIGURE 8. Functional consequences of Thr-55 phosphorylation of SHP in vivo. A, experimental outline is shown at the top. B, the mRNA levels of the
indicated genes were determined by RT-qPCR. C, effects of mutation of Thr-55 on BA pools and hepatic TG levels are shown. D, a glucose tolerance test was
performed and serumglucose levels were detected at the indicated times. Statistical significancewas determined by the Student’s t test, *, **, andNS indicate
p 0.05, p 0.01, and statistically nonsignificant, respectively, S.E. (n 5).
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ilar. Second, Thr-55 phosphorylation is essential for Arg-57
methylation. We recently showed that Arg-57 methylation by
PRMT5 methyltransferase is important for enhancing SHP
repression activity (19). Interestingly, a naturally occurring
mutation of Arg-57 to Trp in SHP is present in human meta-
bolic syndrome patients (20). Third, a recent study of trans-
genic mice has shown that PKC functions as a negative regu-
lator of obesity-induced inflammation and counteracts liver
steatosis (30). This study is in line with our study showing that
PKC-mediated phosphorylation of SHP is important for
reduction of hepatic TG levels. Fourth, PKCwas identified for
the first time as a key regulator of FGF19 as well as BA signaling
in hepatocytes. Our findings indicated that PKC is localized in
the cytoplasm and FGF19 treatment dramatically increases
phosphorylation and nuclear abundance of PKC. Consistent
with these results, phosphorylated PKC was predominantly
located in the nucleus. Moreover, SHP phosphorylated at
Thr-55 was also largely detected in the nucleus. These findings,
together with the increased occupancy of PKC at the Cyp7a1
promoter, suggest that phosphorylation of SHP by activated
PKC likely occurs in the nucleus at the SHP target genes.With
regard to PKC in BA-regulated hepatic function, a recent
study has shown that overexpression of a membrane ATPase,
ATP8B1, results in PKC-mediated phosphorylation of FXR
with enhanced activity and nuclear localization upon BA sig-
naling (31). Our findings, together with this previous study,
suggest that PKCmay coordinately regulate the activity of two
keymediators of BA signaling, FXR and SHP. It will be interest-
ing to see whether PKC and PKC-mediated PTMs of these
regulators play a role in the development of BA-related diseases
including cholestasis, steatosis, and cancer.
The reported studies on the role of SHP in hepatic lipid
metabolism have been inconsistent. Our current study shows
that adenoviral-mediated acute liver-specific overexpression of
SHP WT decreased hepatic TG levels and BA pools and that
PKC-mediated phosphorylation of SHP is important for these
effects. In line with our findings, it was shown that BAs reduce
TG levels by activating the FXR/SHP pathway and that SHP is
essential for BA-mediated down-regulation of hepatic lipogen-
esis by inhibiting expression of Srebp-1c, a key lipogenic activa-
tor (7). In contrast, chronic elevation of hepatic SHP levels in
transgenic mice resulted in decreased BA pools and increased
liver TG levels (21), whereas SHP-KO mice were lean and had
increased (14) or unchanged insulin sensitivity (32). These dif-
ferences may be due to acute versus chronic manipulation of
SHP levels inmice, tomixed genetic backgrounds of transgenic
mice, and also to effects from non-hepatic tissues on the overall
energy balance and metabolic outcomes in the whole body
SHP-KO mice. Inducible liver-specific mouse models will be
valuable to precisely assess these important issues.
An unexpected effect of expression in the liver of the either
WT or SHP mutated at Thr-55 was improved glucose toler-
ance. Glucose tolerance is primarily mediated by glucose
uptake in peripheral tissues, so these results suggest that the
several days of altered metabolism in the liver indirectly affects
the glucose sensitivity of peripheral tissues. Further studies will
be required to determine the mechanism of this effect.
Consistent with the role of SHP in recruiting chromatin-
modifying cofactors (16–18, 33), occupancy of HDACs and
Brm at the tested BA-responsive genes was indeed substantially
decreased by mutation of Thr-55. However, it was surprising
that the occupancy ofG9awas not affected by theThr-55muta-
tion. The underlying mechanisms are not clear but other BA
signal-inducedPTMsof SHPmay be important forG9a recruit-
ment. PTMs of regulatory proteins like SHP change the confor-
mation of the protein interface and thus may selectively alter
interaction with transcriptional regulatory proteins, which
then may contribute to gene-specific regulation. If the regula-
tion of a subset of BA-responsive SHP target genes is more
dependent on promoter occupancy of HDACs and Brm, com-
pared with G9a, then these genes would be selectively depend-
ent on Thr-55 phosphorylation of SHP. Future studies will be
required to determine the molecular basis of gene-specific reg-
ulation by BA signal-induced PTMs of SHP and other key tran-
scriptional regulators.
Epigenomics has emerged as an important aspect of regula-
tion of many biological processes including liver BA metabo-
lism (33). In addition to our studies (16–18) described above,
other recent studies have demonstrated that chromatin-modi-
fying cofactors have a critical role in maintaining BA/choles-
terol homeostasis. MLL3, a histone lysine methyltransferase,
functions as a critical coactivator of FXR and catalyzes trim-
ethylation of K4 of histone H3 at FXR target genes, including
FIGURE9.Proposedmodel.Phosphorylationof SHPbyPKC at a single site is
important for translating BA or FGF19 signaling into epigenomic events at a
subset of liver metabolic genes. Binding of BA or FGF19 to their respective
membrane receptors triggers signaling cascades in hepatocytes, which
results in nuclear translocation and activation of PKC. BA also binds to FXR
and induces BA-responsive genes including Shp. Activated PKC phosphoryl-
ates SHPat Thr-55. Thr-55phosphorylation increases the SHP interactionwith
PRMT5, which is required for subsequent Arg-57methylation. These sequen-
tial PTMs selectively increase the SHP interaction with repressive chromatin
modifying cofactors, HDACs and Brm, and the recruitment of these proteins
to a subset of BA-responsive genes, resulting in histone modifications and
gene repression. PKC is also recruited to SHP target genes, possibly in the
same complex that contains PRMT5 and the chromatin modifiers (16–18).
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the Shp gene and remarkably, inactivation of MLL3 resulted in
disrupted BA homeostasis in vivo (34, 35). Consistent with
these findings, occupancies of MLL3 and H3K4 methylation at
BA transporter genes were decreased in a mouse model of liver
cholestasis (36). Also, the importance of HDAC7 in the feed-
back regulation of CYP7A1 has been reported, revealing
HDAC7 as a potential target for treating hypercholesterolemia
(37). Although BAs have beneficial roles in removing excess
cholesterol and counteracting obesity by reducing TG levels,
abnormally elevated hepatic BA levels are associatedwith hepa-
tobiliary disease, like cholestasis, as recently demonstrated in
SHP-KO (38) and SHP/FXR-KO mouse studies (39). In this
work,wehave shown the crucial role of phosphorylation of SHP
at a single site by PKC in BA signal-induced epigenomic reg-
ulation of liver metabolic genes. Our findings thus suggest that
Thr-55 phosphorylation of SHP may provide a novel potential
target for the treatment of BA-related diseases associated with
SHP dysfunction.
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